References
- Benchimol EI, Fortinsky KJ, Gozdyra P, et al. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflamm Bowel Dis 2011;17:423-39
- Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn’s disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol 2007;5:1424-9
- Ruemmele FM, Veres G, Kolho KL, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease. J Crohns Colitis 2014;8:1179-207
- Edsbacker S, Andersson T. Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn’s disease. Clin Pharmacokinet 2004;43:803-21
- Escher JC. Budesonide versus prednisolone for the treatment of active Crohn’s disease in children: a randomized, double-blind, controlled, multicentre trial. Eur J Gastroenterol Hepatol 2004;16:47-54
- Levine A, Weizman Z, Broide E, et al. A comparison of budesonide and prednisone for the treatment of active pediatric Crohn’s disease. J Pediatr Gastroenterol Nutr 2003;36:248-52
- Levine A, Kori M, Dinari G, et al. Comparison of two dosing methods for induction of response and remission with oral budesonide in active pediatric Crohn’s disease: a randomized placebo-controlled trial. Inflamm Bowel Dis 2009;15:1055-61
- Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohn’s disease activity index. J Pediatr Gastroenterol Nutr 1991;12:439-47
- Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child 1969;44:291-303
- Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in boys. Arch Dis Child 1970;45:13-23
- Turner D, Griffiths AM, Walters TD, et al. Mathematical weighting of the Pediatric Crohn’s Disease Activity Index (PCDAI) and comparison with its other short versions. Inflamm Bowel Dis 2012;18:55-62
- Hyams J, Markowitz J, Otley A, et al. Evaluation of the pediatric crohn disease activity index: a prospective multicenter experience. J Pediatr Gastroenterol Nutr 2005;41:416-21
- Otley A, Smith C, Nicholas D, et al. The IMPACT questionnaire: a valid measure of health-related quality of life in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2002;35:557-63
- Otley A, Xu S, Yan S, et al. IMPACT-III is a valid, reliable and responsive measure of health-related quality of life in pediatric Crohn’s disease. J Pediatr Gastroenterol Nutr 2006;43:S49
- de Onis M, Onyango AW, Borghi E, et al. Development of a WHO growth reference for school-aged children and adolescents. Bull World Health Organ 2007;85:660-7
- World Health Organization. Growth reference 5–19 years. Available at: http://www.who.int/growthref/tools/en/ [Last accessed 22 October 2015]
- Dilger K, Alberer M, Busch A, et al. Pharmacokinetics and pharmacodynamic action of budesonide in children with Crohn’s disease. Aliment Pharmacol Ther 2006;23:387-96
- Rezaie A, Kuenzig ME, Benchimol EI, et al. Budesonide for induction of remission in Crohn’s disease. Cochrane Database Syst Rev 2015;6:CD000296
- Kuenzig ME, Rezaie A, Seow CH, et al. Budesonide for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev 2014;8:CD002913
- Gruvstad E, Hedner LP, Hoglund P, et al. Comparison of methods for evaluation of the suppressive effects of prednisolone on the HPA axis and bone turnover: changes in s-DHEAS are as sensitive as the ACTH test. Int J Clin Pharmacol Ther 2014;52:15-26
- Ledder O, Catto-Smith AG, Oliver MR, et al. Clinical patterns and outcome of early-onset inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2014;59:562-4